Michael Schaapveld

associate staff scientist

The Netherlands Cancer Institute
Country flagNetherlands
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Background: Night shift work may be a risk factor for melanoma, potentially due to suppressed melatonin and decreased vitamin D levels. We examine the potential association between night shift work and melanoma risk using detailed, lifetime information on night shift work in a large cohort of Dutch nurses. Methods: We used questionnaire data from the Nightingale Study obtained from 59,384 (former) female nurses ages 19 to 65 years (median: 48.7; IQR: 39.6–55.3). HRs and 95% confidence intervals for melanoma risk in relation to various lifetime night shift work exposure variables were estimated. Results: During 10 years of follow-up, 307 women developed melanoma. Melanoma risk did not differ between women who worked night shifts and those who never worked night shifts (age-adjusted HR = 0.98; 95% confidence interval, 0.73–1.30). No statistically significantly increased risks were found for a longer night shift work duration, a higher cumulative number of nights worked, a higher number of consecutive nights worked per month, or a shorter time since quitting night shift work. Conclusions: We found no association between night shift work exposure and melanoma risk. Impact: This study should reassure nurses that working night shifts is not associated with an increased risk of melanoma.

Year:

2025

PURPOSE Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages. METHODS We assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses. RESULTS After a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m 2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m 2 doxorubicin ( P trend = .004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR] age <21 years , 1.5 [95% CI, 0.9 to 2.6]; HR age ≥21 years , 1.3 [95% CI, 0.9 to 1.9) or chest RT (HR without mantle/axillary field RT , 1.9 [95% CI, 1.06 to 3.3]; HR with mantle/axillary field RT , 1.2 [95% CI, 0.8 to 1.8]). CONCLUSION This study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

Year:

2024

Collaborators (7)

Jelle Vlaanderen

Senior Scientist

National Institute for Public Health and the Environment

NETHERLANDS
View details

Hans Kromhout

Utrecht University

NETHERLANDS
View details

Josée M. Zijlstra

VU medisch centrum

NETHERLANDS
View details

Marie José Kersten

University of Amsterdam

NETHERLANDS
View details

Pieternella J. Lugtenburg

Erasmus MC

NETHERLANDS
View details

Roel Vermeulen

Prof. at Utrecht University

Utrecht University

NETHERLANDS
View details

Cecile Janus

Erasmus University Rotterdam

NETHERLANDS
View details